These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 36800182

  • 1. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M, Lai H, Na F, Li S, Qiu X, Tian J, Zhang Z, Ge L.
    JAMA Netw Open; 2023 Feb 01; 6(2):e230023. PubMed ID: 36800182
    [Abstract] [Full Text] [Related]

  • 2. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
    Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV.
    Cochrane Database Syst Rev; 2021 Nov 16; 11(11):CD013757. PubMed ID: 34783356
    [Abstract] [Full Text] [Related]

  • 3. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
    Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP.
    Cochrane Database Syst Rev; 2023 Oct 23; 10(10):CD009417. PubMed ID: 37870128
    [Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 5. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM.
    Nurs Womens Health; 2024 Feb 30; 28(1):75-79. PubMed ID: 38070539
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T.
    Lancet Child Adolesc Health; 2023 Mar 30; 7(3):180-189. PubMed ID: 36634694
    [Abstract] [Full Text] [Related]

  • 7. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
    Sanders SL, Agwan S, Hassan M, van Driel ML, Del Mar CB.
    Cochrane Database Syst Rev; 2019 Aug 26; 8(8):CD009417. PubMed ID: 31446622
    [Abstract] [Full Text] [Related]

  • 8. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 26; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M, Respiratory Syncytial Virus (RSV) Prevention study group.
    Lancet Infect Dis; 2015 Dec 26; 15(12):1398-408. PubMed ID: 26511956
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review.
    Gonzales T, Bergamasco A, Cristarella T, Goyer C, Wojdyla M, Oladapo A, Sawicky J, Yee J, Moride Y.
    Am J Perinatol; 2024 May 26; 41(S 01):e1107-e1115. PubMed ID: 36452969
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC, Tripp RA.
    Expert Opin Investig Drugs; 2022 Jan 03; 31(1):23-29. PubMed ID: 34937485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.